Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized Phase II Study of Epcoritamab for Patients With Aggressive B-Cell Lymphomas Achieving a Partial Response After CD19-Directed CAR-T Therapy

NCT06238648 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT06238648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized Phase II Study of Epcoritamab for Patients With Aggressive B-Cell Lymphomas Achieving a Partial Response After CD19-Directed CAR-T Therapy
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Recruiting
Start date
January 31, 2024
Completion date
December 31, 2030
Enrollment
120 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, not otherwise specified, primary mediastinal large b-cell lymphoma, transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma